



COMPANY OVERVIEW

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.

NeoGenomics To Attend The 16th Annual Craig-Hallum Institutional Investor Conference

May 23 2019, 4:30 PM EDT

NeoGenomics Announces Pricing on Public Offering of Common Stock

May 21 2019, 8:10 PM EDT

NeoGenomics Announces Proposed Public Offering of Common Stock

May 20 2019, 4:12 PM EDT

STOCK OVERVIEW

| | |
|---------------|-------------------|
| Symbol | NEO |
| Exchange | Nasdaq |
| Market Cap | 2.03b |
| Last Price | \$21.25 |
| 52-Week Range | \$11.05 - \$23.85 |

05/24/2019 04:00 PM EDT

INVESTOR RELATIONS

William Bonello
Chief Strategy and Corporate
Development Officer
Director, Investor Relations
T: (239) 690-4238
M: (239) 284-4314
bill.bonello@neogenomics.com

MANAGEMENT TEAM

Douglas M. VanOort
Chairman of the Board of Directors and Chief Executive Officer

Sharon Virag
Chief Financial Officer

Robert J. Shovlin
President, Clinical Services

George A. Cardoza
President, Pharma Services

Jennifer M. Balliet
Chief Culture Officer

William Bonello
Chief Strategy and Corporate Development Officer
Director, Investor Relations

Denise E. Pedulla
General Counsel

Steven A. Ross
Vice President, Chief Information Officer

Stephanie Bywater
Chief Compliance Officer

Steven G. Brodie, Ph.D.
Vice President of Worldwide Pharma Services Operations

Kathryn B. McKenzie
Vice President - Finance, Principal Accounting Officer

Lawrence M. Weiss, M.D.
Chief Scientific Officer

NEOGENOMICS, INC.

12701 Commonwealth Dr.
Suite 9
Fort Myers, FL 33913

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.